Research and Markets: Rapid Cancer Pain Management Growth to Push Global Revenue to $7 Billion by 2019
This is especially true since pain can come from a wide variety of ailments including, but not limited, to headaches, low back pain, arthritis pain, cancer pain, and neurogenic pain, which is from an injury to the central nervous system or peripheral nerves. Doctors have a variety of ways to diagnose pain, but the first step should be getting a detailed history of how and when the pain began, what it feels like, and if it has progressively gotten worse. Often, the person with pain is referred to a specialist. The specialist might be a neurologist, orthopedist, or anesthesiologist, among others, depending on the suspected problem. There are also many tests at a doctors disposal including computer-assisted tomography (CAT scan), magnetic resonance interferometry (MRI), and electromyography to aid in a pain diagnosis. Solutions can range from medications to physical therapy, yet for some people a definitive diagnosis cannot be found, and the usual treatment options do not provide pain relief. Patients will often get the message that the doctor cant find anything wrong, so they will just have to live with their condition , says Dr. Clarke, who is also the author of the book They Cant Find Anything Wrong!.
For the original version including any supplementary images or video, visit http://www.everydayhealth.com/pain-management/is-chronic-pain-all-in-your-head.aspx
Mon Jul 15, 2013 12:38pm EDT Research and Markets: Rapid Cancer Pain Management Growth to Push Global Revenue to $7 Billion by 2019 Research and Markets ( http://www.researchandmarkets.com/research/66w3g4/pain_management ) has announced the addition of the “Pain Management Therapeutics Market to 2019 – Impact of Patent Expiries Offset by Demand for Neuropathic and Rheumatoid Pain Medications and Strong Pipeline” report to their offering. The cancer pain management market is expected to be the fastest growing segment within the global pain management therapeutics market, achieving sales of $7 billion by 2019 The new report* states that the cancer pain management market will increase at a Compound Annual Growth Rate (CAGR) of 9.1% from 2012 to 2019, followed closely by the post-operative market boasting an estimated increase of 8% over the forecast period. It will also become the second largest segment of the overall pain management market, claiming 15%, while the neuropathic pain management market will continue to hold the largest share of 16%. According to the authors, the growth of the cancer pain management sector will be driven by the increasing global prevalence of cancer, with drugs such as Fenota, Nucynta, Remoxy and Abstral leading the market. (Quote: Something including the number of people suffering with cancer pain globally / how much this is expected to increase by / the current unmet needs in the market.) The significant growth of this treatment area will help boost the growth of the overall pain management market, which the authors estimate will rise from $36 billion in 2012 to $49 billion in 2019, representing a CAGR of 4.6%. A healthy pipeline will also contribute to climbing market revenue, with neuropathic pain being the key therapy area of R&D focus, followed by migraine pain, which currently claims 14% of the pipeline. Despite this level of activity, the overall pain management market will be prevented from growing any further due to the challenges posed by generic competition, which is expected to increase over the coming years following a series of patent expiries for top-selling drugs such as Cymbalta, Lyrica and Celebrex (celecoxib).
For the original version including any supplementary images or video, visit http://www.reuters.com/article/2013/07/15/research-and-markets-idUSnBw156038a+100+BSW20130715